BA
NVO

Ballew Advisors’s Novo Nordisk NVO Stock Holding History

Ballew Advisors’s Portfolio NVO Stock Details NVO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-1,994
Closed -$233K – 108
2024
Q3 		$233K Buy
1,994
+22
+1% +$2.93K 0.16% 95
2024
Q2 		$279K Buy
1,972
+304
+18% +$40.3K 0.18% 85
2024
Q1 		$208K Buy
+1,668
New +$199K 0.14% 96

Other funds holding NVO

Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
GQG Partners
GQG Partners Ft. Lauderdale, Florida $63.1B AUM 23.07% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return
Koshinski Asset Management
Koshinski Asset Management Decatur, Illinois $1.6B AUM 20.7% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
Fayez Sarofim & Co
Fayez Sarofim & Co Houston, Texas $39.1B AUM 15.14% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
F
Folketrygdfondet Oslo Norway, Norway $5.64B AUM 47.16% 1-Year Est. Return

Ballew Advisors's NVO Position: Q4 2024 in Review

Ballew Advisors sold out of Novo Nordisk (NVO) in Q4 2024, closing a stake of 1,994 shares — an estimated $233K sold.

Ballew Advisors first reported a position in NVO in Q1 2024 and held it in 3 quarters. The position peaked at $279K in Q2 2024. 1,663 funds tracked by Wall St. Rank hold NVO as of Q4 2024.

  • Ballew Advisors reported no remaining Novo Nordisk position as of Q4 2024 after selling out during the quarter.
  • Ballew Advisors sold 1,994 Novo Nordisk shares in Q4 2024, an estimated $233K.
  • Ballew Advisors first reported a position in Novo Nordisk in Q1 2024 and held it in 3 quarters.
  • Ballew Advisors's Novo Nordisk position peaked at $279K in Q2 2024.
  • 1,663 funds tracked by Wall St. Rank held Novo Nordisk as of Q4 2024.

Based on Ballew Advisors's 13F filing for Q4 2024, filed 15 Jan 2025.